LLY Dec 2025 470.000 put
| Previous close | 8.40 |
| Open | 8.40 |
| Bid | 5.45 |
| Ask | 10.20 |
| Strike | 470.00 |
| Expiry date | 2025-12-19 |
| Day's range | 8.40 - 8.40 |
| Contract range | N/A |
| Volume | |
| Open interest | 55 |
Investor's Business DailyWhy Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
Amgen stock dipped Monday after an analyst downgraded shares, saying the opportunity for its weight-loss drug is already baked into the stock.
Insider MonkeyEli Lilly and Company (LLY): Growth Driven by Patents and Pipeline Milestones
We recently published a list of Stocks On the Rise: 8 Best Stocks to Invest in Now. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best rising stocks to invest In now. The market experts believe that Q3 2024 saw stocks experience increased […]
Barrons.comAmgen Stock Falls. The Obesity Drug Landscape Is Getting Crowded.
Amgen has a lot riding on an experimental obesity drug that it hopes will rival those of Eli Lilly and Novo Nordisk But one analyst argues that mounting competition in weight-loss drugs will make it harder for the stock to benefit. Truist analyst Srikripa Devarakonda downgraded Amgen to Hold from Buy on Monday, while raising the firm’s target for the stock price to $333 from $320. Like most pharmaceutical companies, Amgen trades much based on how it progresses in developing new drugs.
